Bone Health After Cancer Treatment: Who Needs a DXA, and When
Aromatase inhibitors, androgen deprivation, steroids, transplant, and early menopause all accelerate bone loss. A practical screening and treatment cadence for survivors and primary care.
Several of the most effective cancer therapies accelerate bone loss, and the fracture that results often arrives a decade after anyone was thinking about the drug that caused it. Bone health is one of the easiest survivorship gaps to close because the screening test is cheap and the treatments work.
Who is at risk, and why
Aromatase inhibitors remove the residual estrogen that protects bone in postmenopausal women, producing bone loss faster than natural menopause. Androgen deprivation therapy does the equivalent in men, and the loss is steepest in the first year.
Chemotherapy-induced ovarian failure creates abrupt early menopause in younger survivors, who then accumulate decades of low-estrogen exposure. Stem-cell transplant, chronic corticosteroids, and some targeted agents add their own effect.
Radiation to a bony field creates focal risk that a hip and spine DXA can miss. Insufficiency fracture in a radiated field is a distinct entity worth naming in the record.
A screening cadence you can actually run
Order a baseline DXA when a bone-active therapy starts, or at the first survivorship visit if that moment has passed. Repeat every one to two years while the exposure continues, and consider a fracture-risk calculation alongside the score.
Check vitamin D and correct deficiency before interpreting a marginal score. Ask about height loss and any low-trauma fracture, which changes the category regardless of the number.
What actually protects bone
Progressive resistance training and weight-bearing impact activity are the non-pharmacologic interventions with real evidence. Adequate dietary calcium and repletion of vitamin D are supportive rather than sufficient.
When the score or fracture history crosses the treatment threshold, bisphosphonates or denosumab are the standard options, chosen with the oncology team because some of these agents also have anti-cancer indications in specific settings.
Fall risk deserves the same attention as bone density. Neuropathy after platinum or taxane therapy raises fall risk substantially, and a fall on fragile bone is the event everything else is trying to prevent.
Frequently asked questions
- I finished endocrine therapy years ago. Is a DXA still worth it?
- Yes, if you have never had one. Bone lost during therapy is not automatically regained afterward, and a single baseline tells you whether anything further is needed.
- Do supplements alone protect bone during aromatase inhibitor therapy?
- No. Calcium and vitamin D correct deficiency but do not offset drug-driven loss on their own. Screening determines whether pharmacologic treatment is needed.
- Is a normal DXA reassuring after chest or pelvic radiation?
- Only partly. Standard sites can look normal while a radiated field carries focal insufficiency-fracture risk, so new focal bone pain in a treated field still deserves imaging.